Skip to Content
Is technology key to beating breast cancer? Learn more >

Trastuzumab Pregnancy and Breastfeeding Warnings

Trastuzumab is also known as: Herceptin

Trastuzumab Pregnancy Warnings

Use should be avoided. AU TGA pregnancy category: D US FDA pregnancy category: D Comments: -Advise women of the potential hazard to the fetus. -Women of childbearing potential should use effective contraception during treatment and for 7 months after the last dose.

Animal studies showed no evidence of harm to the fetus or impairment of fertility. The drug crossed the placental barrier. There are no adequate or well-controlled studies in pregnant women. Post marketing reports showed cases of oligohydramnios which resulted in impairment of fetal renal growth and/or function, pulmonary hypoplasia including fatalities, skeletal abnormalities, and neonatal death. To monitor the outcomes of pregnant women exposed to this drug, a pregnancy registry has been established. Physicians are encouraged to register patients and pregnant women are encouraged to register themselves at AU TGA pregnancy category D: Drugs which have caused, are suspected to have caused or may be expected to cause, an increased incidence of human fetal malformations or irreversible damage. These drugs may also have adverse pharmacological effects. Accompanying texts should be consulted for further details. US FDA pregnancy category D: There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

See references

Trastuzumab Breastfeeding Warnings

Use is not recommended and a decision should be made to discontinue breastfeeding or discontinue the drug, taking into account the importance of the drug to the mother. Excreted into human milk: Unknown Excreted into animal milk: Yes Comments: Breastfeeding should be avoided during therapy and for 7 months after the last dose.

See references

References for pregnancy information

  1. "Product Information. Herceptin (trastuzumab)." Genentech, South San Francisco, CA.
  2. Cerner Multum, Inc. "Australian Product Information." O 0
  3. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  4. Waterston AM, Graham J "Effect of adjuvant trastuzumab on pregnancy." J Clin Oncol 24 (2006): 321-2

References for breastfeeding information

  1. Cerner Multum, Inc. "Australian Product Information." O 0
  2. "Product Information. Herceptin (trastuzumab)." Genentech, South San Francisco, CA.
  3. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0

See Also...

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.